Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Susceptibility of paramyxoviruses and filoviruses to inhibition by 2'-monofluoro- and 2'-difluoro-4'-azidocytidine analogs

Michael K. Lo\textsuperscript{b,∗}, Paul C. Jordan\textsuperscript{b}, Sarah Stevens\textsuperscript{b}, Yuen Tam\textsuperscript{b}, Jerome Deval\textsuperscript{b}, Stuart T. Nichol\textsuperscript{a}, Christina F. Spiropoulou\textsuperscript{a,∗∗}

\textsuperscript{a} US Centers for Disease Control and Prevention, Atlanta, GA, USA
\textsuperscript{b} Alios BioPharma, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, South San Francisco, CA, USA

\textbf{A R T I C L E I N F O}

\textbf{Keywords:}
Nucleoside analog
Filovirus
Ebola virus
Paramyxovirus
Henipavirus
Nipah virus
R1479
Antiviral

\textbf{A B S T R A C T}

Ebolaviruses, marburgviruses, and henipaviruses are zoonotic pathogens belonging to the Filoviridae and Paramyxoviridae families. They exemplify viruses that continue to spill over into the human population, causing outbreaks characterized by high mortality and significant clinical sequelae in survivors of infection. There are currently no approved small molecule therapeutics for use in humans against these viruses. In this study, we evaluated the antiviral activity of the nucleoside analog 4'-azidocytidine (4'\textsuperscript{N3}-C, R1479) and its 2'-monofluoro- and 2'-difluoro-modified analogs (2F-4'\textsuperscript{N3}-C and 2dif-4'\textsuperscript{N3}-C) against representative paramyxoviruses (Nipah virus, Hendra virus, measles virus, and human parainfluenza virus 3) and filoviruses (Ebola virus, Sudan virus, and Ravn virus). We observed enhanced antiviral activity against paramyxoviruses with both 2dif-4'\textsuperscript{N3}-C and 2F-4'\textsuperscript{N3}-C compared to R1479. On the other hand, while R1479 and 2dif-4'\textsuperscript{N3}-C inhibited filoviruses similarly to paramyxoviruses, we observed 10-fold lower filovirus inhibition by 2F-4'\textsuperscript{N3}-C. To our knowledge, this is the first study to compare the susceptibility of paramyxoviruses and filoviruses to R1479 and its 2'-fluoro-modified analogs. The activity of these compounds against negative-strand RNA viruses endorses the development of 4'-modified nucleoside analogs as broad-spectrum therapeutics against zoonotic viruses of public health importance.

\section{1. Introduction}

In the decades prior to 2014, human outbreaks of emerging zoonotic viruses causing fatal hemorrhagic fever, such as Ebola virus (EBOV), or encephalitis, such as Nipah virus (NIV), have been relatively sporadic and small in terms of case numbers, ranging from isolated single cases to several hundred cases (CDC, 2017; Luby and Gurley, 2012). The historically largest EBOV outbreak of 2013–2016 highlighted the relative paucity of efficacious therapeutics and vaccines available to deploy against such pathogens, despite extensive pre-clinical studies demonstrating efficacy of therapeutic antibodies and vaccines for these biosafety level-4 pathogens (Broder et al., 2016; Geisbert et al., 2014; Mendoza et al., 2017; Mire et al., 2016; Qiu et al., 2014). To identify therapeutics that could be repurposed against EBOV, in vitro screens of libraries of FDA-approved compounds have been conducted, screening, among others, antiviral nucleoside and nucleotide analogs (Madrid et al., 2015; Veljkovic et al., 2015; Welch et al., 2016). Over the last 30 years, the development of antiviral nucleoside and nucleotide analogs was primarily directed towards combating viruses responsible for chronic infections such as human immunodeficiency virus, herpes viruses, and hepatitis viruses (Ray and Hitchcock, 2009). In 2006, Klumpp and colleagues first demonstrated the in vitro activity of 4'-azidocytidine (4'\textsuperscript{N3}-C, R1479) against hepatitis C virus (HCV), a single-stranded, positive-sense RNA virus (Klumpp et al., 2006). The development of R1479 and its produg balapiravir was halted following findings of toxicity and low efficacy of these compounds in clinical trials for treating HCV and Dengue virus (Nelson et al., 2012; Nguyen et al., 2013). Despite this, the in vitro activity of R1479 against diverse flaviviruses of public health importance, such as Dengue virus and tick-borne encephalitis virus, suggested that it may be a template for developing modified analogs with antiviral activity (Chen et al., 2014; Eyer et al., 2016). Interestingly, R1479 and other 4'-modified analogs have recently been shown to also inhibit respiratory syncytial virus (RSV), a single-stranded, negative-sense RNA virus (Clarke et al., 2015; Deval et al., 2015; Wang et al., 2015). Following those studies, we described potent antiviral activity of R1479 against representative...
members of the Paramyxoviridae family, including the henipaviruses, NiV and Hendra virus (HeV) (Hotard et al., 2017). Given the in vitro antiviral properties of R1479 and its 2′-mono and 2′-difluoro analogs (2′F-4′N3-C and 2′dif-4′N3-C, respectively) against RSV (Deval et al., 2015), and the highly conserved nucleotide binding domains shared across Pneumoviridae, Paramyxoviridae, and Filoviridae families (Lo et al., 2017), we evaluated and compared the antiviral potencies of these cytidine analogs against representative paramyxoviruses and filoviruses including the 2014 Makona variant of EBOV (Albarino et al., 2015). Our study documents the susceptibility of paramyxoviruses and filoviruses to R1479 and its 2′-fluoro-modified analogs, and reinforces the prospect of developing 4′-modified nucleoside analogs as potential broad-spectrum therapeutics against RNA viruses of public health importance.

2. Materials and methods

2.1. Biosafety

All work with infectious virus was performed in Class 2 Biosafety cabinets, and all work utilizing live Nipah virus (NiV), Hendra virus (HeV), Ebola virus (EBOV), Sudan virus (SUDV), Ravn virus (RAVV), Marburg virus (MARV), and Rift Valley Fever virus (RVFV) was conducted in a BSL-4 laboratory at the Centers for Disease Control and Prevention (CDC, Atlanta, GA).

2.2. Cells, viruses, and compounds

HeLa, SK-N-MC, and NCI-H358 cells were purchased from the American Type Tissue Culture Collection (ATCC, Manassas, VA, USA). HeLa and SK-N-MC cells were propagated in Dulbecco’s modified Eagle medium (DMEM; Life Technologies, Carlsbad, CA, USA) supplemented with 10% (vol/vol) fetal calf serum (FCS; Hyclone; Thermo Scientific, Waltham, MA, USA) and penicillin-streptomycin (Life Technologies). NCI-H358 cells were propagated in Roswell Park Memorial Institute medium (RPMI 1640), supplemented with 10% FCS. HuH7 cells were obtained from Apath, LLC (Brooklyn, NY, USA), and propagated in DMEM supplemented with 10% FCS and 1× nonessential amino acids (Life Technologies). Normal human small airway epithelial cells (SAECs) were purchased from ATCC and propagated in Airway Epithelial Cell Basal medium supplemented with the Bronchial Epithelial Cell Growth Kit (ATCC).

NiV (Malaysian genotype), recombinant NiV Malaysian genotype expressing ZsGreen1 fluorescent protein (NiV-GFP2AM) (Lo et al., 2014), HeV, recombinant Measles virus (MV) (Edmonston-Zagreb strain) expressing enhanced green fluorescent protein (rMVΔEGFP(3)) (Rennick et al., 2015), EBOV (Makona variant), recombinant EBOV (Mayinga variant) (representative of Ebolavirus genus), SUDV (Gulu variant) (Sanchez and Rollin, 2005), RAVV (Bat371 variant) (Johnson et al., 1996), and recombinant RVFV expressing enhanced green fluorescent protein (RVFV-GFP, ZH501) (Bird et al., 2007) were propagated in either Vero E6 (ATCC CRL-1586) or Vero (ATCC CCL-81) cells, and were quantitated by the number of cells and reported as picomoles per milliliter.

2.3. Single nucleotide incorporation by recombinant RSV L-P

Recombinant RSV L-P was produced through the co-expression of RSV L and P proteins in a baculovirus expression system, according to previously described procedures (Noton et al., 2012). The reaction mixture was composed of 0.2 μM modified template sequence (UCCGUUGUUU), 0.2 μM recombinant RSV L-P polymerase, 200 μM 5′-pACGG primer, buffer (20 mM Tris pH 7.5, 10 mM KCl, 6 mM MgCl2, 2 mM DTT, 0.01% Triton, 10% DMSO), and (α-32P)-GTP with a final volume of 10 μL. The reaction was started through the addition of NTPs, incubated at 30°C for 30 min, and quenched through the addition of gel loading buffer (Ambion). Samples were run for 1.5 h at 80 W in a 22.5% polyacrylamide urea sequencing gel. The gel was then exposed to a phosphor-screen, and scanned.

2.4. Measurement of nucleoside triphosphate (NTP) formation

R1479 triphosphate (TP) formation was measured in HeLa, HuH7, SK-N-MC, and NCI-H358 cells. 2′F-4′N3-CTP, and 2′dif-4′N3-CTP formation were measured in HeLa and NCI-H358 only. The cells were maintained and cultured at Allos BioPharma. The cells were seeded in six-well plates at 1.5 × 104 cells/well with their corresponding media and incubated overnight in a cell culture incubator at 37°C and 5% CO2 before use. In the experiment, 50 μM of R1479, 2′F-4′N3-C, or 2′dif-4′N3-C was added to each well, incubated for 24 h at 37°C and 5% CO2. At the end of the incubation, the medium was removed and cells were washed twice with cold 0.9% sodium chloride in water. The cells were lysed with methanol/water (70%/30%, v/v), and the extracted supernatant was dried and reconstituted in 1 mM ammonium phosphate before LC/MS/MS analysis to determine the corresponding R1479-TP, 2′F-4′N3-TP, and 2′dif-4′N3-TP levels (Chen et al., 2009). The concentrations of the R1479-TP, 2′F-4′N3-TP, and 2′dif-4′N3-TP were normalized by the number of cells and reported as picomoles per million cells.

2.5. Recombinant reporter virus assays

All viruses expressing fluorescent (GFP, ZsGreen) proteins were assayed for fluorescence by using an H1 Synergy plate reader (Biotek). NCI-H358 cells or SAECs were seeded at 2 × 104 cells per well in black opaque 96-well plates (Corning 3619, Corning, NY) or Perkin-Elmer CellCarrier Ultra plates (Waltham, MA) and compounds were added to the assay plates for 1 h. Assay plates were transferred to the BSL-4 suite (where appropriate), and infected with 0.25–0.5 TCID50 per cell of the respective virus, and were read between 48 and 168 h post-infection (hpi) depending on the virus used. Fluorescence signal from DMSO-treated infected cells were set as 100% GFP. 50% effective concentrations (EC50) were calculated using four-parameter variable slope non-linear regression of mean values of assays performed in quadruplicate (Graphpad Prism 6, La Jolla, CA).

2.6. Cytotoxic effect (CPE) inhibition and cell viability assays

NCI-H358 cells or SAECs were seeded at 2 × 104 cells per well in white opaque 96-well plates, and compounds were added to the assay plates. Assay plates were transferred to the BSL-4 suite and infected with 0.25–0.5 TCID50 per cell, and were analyzed with CellTiter-Glo 2.0 (Promega, Madison, WI) between 72 and 96 h post-infection (pi) in a HD1 Synergy plate reader. Values were normalized to uninfected cell controls according to % viability as follows: % viability = ([specific value-reference value]/(DMSO control value – reference value)) × 100. Reference values were derived from control wells without cells. Uninfected cell control values (after subtraction of reference values) were set at 100% inhibition of CPE. EC50 values were calculated using four-parameter variable slope non-linear regression fitting of values. The CellTiter-Glo 2.0 assay was also used to determine viability of...
uninfected NCI-H358 cells treated with 3-fold serial dilutions of the compounds for 72 h (3 days) or 168 h (7 days). Values were normalized to DMSO controls according to % viability as follows: % viability = [(specific value-reference value)/(DMSO control value – reference value)] × 100. Reference values were derived from control wells without cells. DMSO control values (after subtraction of reference values) were set at 100% viability. 50% viability/cytotoxicity (CC50) values were calculated using four-parameter variable slope non-linear regression fitting of mean values derived from quadruplicate samples.

2.7. Quantitative focus-forming unit (FFU) assay

To measure compound inhibition of filovirus infection and spread, 2 × 10^4 NCI-H358 cells or SAECs treated with compound were infected with 0.5 TCID50 of EBOV, SUDV, RAVV, or MARV-ZsG. At 7 days pi, cells were fixed in 10% formalin supplemented with 0.2% Triton-X detergent, and stained with primary rabbit anti-EBOV polyclonal serum (Bethyl Laboratories, Bethesda, MD) was added (1:1000) for 1 h. After 3 washes, filovirus infection-induced focus forming units (FFU) were measured in each well of the 96-well plate (CellCarrier-96, Perkin Elmer, Waltham, MA)
using a Cytation5 cell imaging multi-mode reader paired with Gen5 software (Biotek, Winooski, VT). For MARV-ZsG, GFP+ cells were counted directly at 3 days pi without need for fixation and antibody staining. A 2.74× objective lens was used to take 12 overlapping images encompassing each entire well, which were assembled and then analyzed for FFUs ranging in size from 15-200 μm, and which had a relative fluorescence signal that was above 2000. The camera gain was set at 15.6, with an integration time of 306 msec, using an LED intensity setting of 10. The average number of background cell counts were subtracted from each well to give normalized cells counts, and any negative values were adjusted to “0”. For analysis of each experimental replicate, the highest number of positive counts was regarded as 100%, while 0 counts was used for 0% positivity. Following this normalization, data were fitted to a 4-parameter variable slope non-linear regression fitting of mean values derived from quadruplicate samples.

2.8. Infectious virus yield reduction assays

To measure compound inhibition of infectious filovirus yield, 2 × 10^4 NCI-H358 cells were infected with 0.5 TCID_{50} of SUDV or RAVV per cell for 1 h. Virus inoculum was then removed, cells were washed once with phosphate buffered saline, and replaced with culture medium containing respective compound in a 10-point 3-fold dilution series. At 7 days pi, supernatants were harvested, serially diluted (10-fold) and mixed with 10^4 Vero cells per well in 96 well plates. At 5 pi, plates were fixed with 10% formalin supplemented with 0.2% Triton-X detergent, and stained with primary rabbit anti-EBOV serum, and after several washes the corresponding anti-rabbit Dylight 488 conjugated secondary antibody was added. Plates were visually assayed using a microscope for fluorescent cells, and quantitated by 50% tissue TCID_{50} assay using the Reed and Muench method (Reed and Muench, 1938). EC_{50} values were calculated using four-parameter variable slope non-linear regression fitting of mean values derived from quadruplicate samples. Similarly, to measure compound inhibition of infectious henipavirus yield, 2 × 10^4 NCI-H358 cells were infected with 0.25 TCID_{50} of NIV or HeV per cell for 1 h. Virus inoculum was then removed, cells were washed once with phosphate buffered saline, and replaced with culture medium containing compound in a 10-point 3-fold dilution series. At 48 h pi supernatants were harvested, serially diluted, and mixed with 10^4 Vero cells per well in 96-well plates. At day 5 pi, plates were visually assayed for CPE, and then virus titers were quantitated by 50% tissue TCID_{50} assay using the Reed and Muench method (Reed and Muench, 1938). EC_{50} values were calculated using four-parameter variable slope non-linear regression fitting of mean values derived from quadruplicate samples.

3. Results

3.1. Triphosphate forms of R1479 and its 2′- mono- and 2′-difluoro-modified analogs inhibit RSV polymerase activity by acting as RNA chain terminators

To confirm the antiviral mechanism of action of R1479 and its 2′-mono and 2′-difluoro-modified analogs (depicted in Fig. 1a, b, and c respectively), we first performed cell-free in vitro RSV polymerase assays. The RSV polymerase forms a dimer of the L and P protein (RSV L-P) that accepts RNA templates with a primer to generate short RNA synthesis products (Fig. 1d) (Noton et al., 2012). RSV L-P extends the primer by 1 base with the addition of (α-32P)-GTP (Fig. 1e, lane 1) and fully it extends by 7 bases with the addition of ATP and CTP (Fig. 1e, lane 3). We individually substituted the 3 cytidine analogs in place of natural CTP to understand their potential effects as non-obligatory chain terminators in an RNA synthesis assay (Fig. 1e, lanes 4–6). R1479-TP, 2′-F-4′N_{3}-CTP, and 2′-F-4′N_{3}-CTP terminated RNA synthesis by RSV L-P at position +8, and were recognized almost equally by the enzyme. This is consistent with observations of other 2′ and 4′-modified cytidine analogs that inhibit RSV polymerase in similar assays (Deval et al., 2015).

3.2. Intracellular phosphorylation levels of R1479, 2′-F-4′N_{3}-C, and 2′-difluoro-4′N_{3}-C are highly dependent on cell type

In a previous study, we observed different levels of R1479 antiviral activity against henipaviruses depending on the cell line used, with consistently lower R1479 antiviral activity in HeLa cells than in a human epithelial lung carcinoma cell line (NCI-H358) (Hotard et al., 2017). To investigate whether this difference was due to cellular phosphorylation levels of R1479, we measured intracellular phosphorylation of R1479 in 4 human cell lines: HeLa, a cervical adenocarcinoma line; Huh7, a hepatoma line; SK-N-MC, a neuroepithelioma line; and NCI-H358. Each cell line was treated with R1479 for 24 h, and intracellular triphosphate levels were then measured using tandem liquid chromatography/mass spectrometry (LC/MS/MS) and quantitated using synthetic standards. Levels of the corresponding triphosphate (R1479-TP) were measured in each of the 4 cell lines, with highest R1479-TP levels seen in NCI-H358 cells (391 ± 72 pmol/million cells; Fig. 2a). Phosphorylation of R1479 was lowest in Huh7 cells and SK-N-MC cells (18 ± 6.0 and 42 ± 10 pmol/million cells, respectively), and
intermediate in HeLa cells (136 ± 21 pmol/million cells). In addition to R1479, which contains a 4'-azido substitution, we examined the effects of 2'-monofluorou or 2'-difluoro substitutions on NTP levels using the 2 cell lines with the highest NTP levels. HeLa and NCI-H358 cells were treated with 2F-4'N3-C and 2dif-4'N3-C for 24 h at 50 μM, and NTP formation was measured and quantified as previously described (Fig. 2b). In both cell lines, 2F-4'N3-C levels were highest, followed by R1479 and then 2F-4'N3-C, but higher overall NTP levels of all 3 nucleosides were seen in NCI-H358 cells. In light of these results, we decided to use NCI-H358 cells for our cell-based viral infection assays.

3.3. R1479, 2F-4'N3-C, and 2dif-4'N3-C show minimal cytotoxicity in NCI-H358 cells

To ensure that the antiviral effects we observed in this study were not due to any cytotoxic effects attributed to the compounds themselves, we measured the viability of NCI-H358 cells continually incubated with varying dilutions of each compound for 3 and 7 days (Fig. 3). All 3 compounds produced low cytotoxicity 3 days post treatment, and R1479 and 2dif-4'N3-C resulted only in mild cytotoxicity at the highest concentration used (100 μM) after 7 days of treatment (Fig. 4b). Even 7 days post treatment, 50% cell cytotoxicity (CC50) levels were not reached.

3.4. 2F-4'N3-C and 2dif-4'N3-C show superior antiviral activity compared to R1479 against recombinant reporter NIV, RSV, measles virus, and human parainfluenza virus 3

We initially evaluated the antiviral activity of R1479, 2F-4'N3-C, and 2dif-4'N3-C against recombinant reporter RSV (rgRSV224; Hallak et al., 2000), measles virus (rMV3EGFP3; Renwick et al., 2015), human parainfluenza virus-3 (hPIV3-GFP; Zhang et al., 2005), and NIV (NIV-GFP2AM; Lo et al., 2014), expressing green fluorescent reporter proteins (Fig. 4). Whereas EC50 values for R1479 against all 4 viruses were consistently in the single-digit micromolar range, both 2F-4'N3-C and 2dif-4'N3-C inhibited each virus 3- to 20-fold more potently than R1479 (Table 1). 2F-4'N3-C and 2dif-4'N3-C inhibited rRSV224 and rMV3EGFP3 at similar concentrations (Table 1), but 2F-4'N3-C was measurably more potent than 2dif-4'N3-C against hPIV3-GFP (Fig. 4c, Table 1). 2F-4'N3-C also inhibited NIV-GFP2AM moderately more strongly than 2dif-4'N3-C as measured by both a GFP reporter assay (Fig. 4d) and CPE inhibition assay (data not shown; Table 1).

3.5. 2F-4'N3-C and 2dif-4'N3-C reduce both henipavirus-induced CPE and infectious virus yield more strongly than does R1479

We further evaluated the antiviral activity of 2F-4'N3-C and 2dif-4'N3-C against wild-type NIV and HeV by measuring the inhibition of henipavirus-induced CPE and infectious virus yield (Fig. 5). Similar to what was observed for NIV-GFP2AM, 2F-4'N3-C and 2dif-4'N3-C inhibited NIV- and HeV-induced CPE with significantly greater potency than R1479, with 2F-4'N3-C being marginally more potent than 2dif-4'N3-C (Fig. 5a and b). Accordingly, ~1.5 μM 2F-4'N3-C and ~3 μM 2dif-4'N3-C reduced infectious henipavirus yields by 4–5 orders of magnitude (Fig. 5c and d), whereas 6–10 μM R1479 was required for similar virus yield reduction (Hotard et al., 2017). Although in this assay, EC50 values for 2F-4'N3-C and 2dif-4'N3-C were identical against HeV and were within 3-fold against NIV (Table 1), 2F-4'N3-C caused a sharper decline in both NIV and HeV titers than did 2dif-4'N3-C (Fig. 5c and d).

3.6. EBOV variants are susceptible to inhibition by R1479 and 2dif-4'N3-C, but are less susceptible to 2F-4'N3-C inhibition

Recent work describing the broad-spectrum activity of adenosine nucleotide analog GS-5734 across Paramyxoviridae, Pneumoviridae, and Filoviridae families documented conserved amino acids in the nucleotide-binding domains of polymerases of these viruses, which may explain their susceptibility to similar compounds (Lo et al., 2017). In light of this work, alongside other studies documenting the antiviral activity of R1479, 2F-4'N3-C, and 2dif-4'N3-C against both HCV and RSV (Deval et al., 2015; Klump et al., 2006; Smith et al., 2007, 2009; Wang et al., 2015), we tested the antiviral activities of these compounds against recombinant reporter Mayinga and Makona EBOV variants (genus Ebolaovirus, species Zaire ebolavirus) expressing green fluorescent proteins (Albarino et al., 2015; Towner et al., 2005) (Fig. 6a and b). R1479 and 2dif-4'N3-C inhibited both EBOV variants similarly to hepatitis C virus (HCV) and RSV (Deval et al., 2015; Klump et al., 2006; Smith et al., 2007, 2009; Wang et al., 2015). An 10 μM R1479 dose was required for similar virus yield reduction (Hotard et al., 2017). Although in this assay, EC50 values for 2F-4'N3-C and 2dif-4'N3-C were identical against HeV and were within 3-fold against EBOV (Table 1), 2F-4'N3-C caused a sharper decline in both NIV and HeV titers than did 2dif-4'N3-C (Fig. 5c and d).
Fig. 4. Antiviral activity of R1479, 2′F-4′N3-C, and 2′diF-4′N3-C against reporter pneumo- and paramyxoviruses. Representative dose response curves for R1479 (green circles), 2′F-4′N3-C (blue triangles), and 2′diF-4′N3-C (red squares) against recombinant reporter (a) respiratory syncytial virus (rgRSV224), (b) measles virus (rMVezGFP(3)), (c) human parainfluenza virus 3 (hPIV3-GFP), and (d) Nipah virus (NiV-GFP2AM). Data points and error bars indicate the mean value and standard deviation of 4 biological replicates, and are representative of at least 2 independent experiments for each compound.

Table 1
Mean antiviral activity and selective indices of R1479, 2′F-4′N3-C, and 2′diF-4′N3-C in NCI-H358 cells.

| Family            | Virus     | Species/Variant | Assay   | EC_{50} (μM) [SI] |
|-------------------|-----------|-----------------|---------|-------------------|
|                   |           |                 |         | R1479            | 2′diF-4′N3-C | 2′F-4′N3-C |
| **Paramyxoviridae** | NIV       | Rec. M-GFP2AM   | REP     | 3.1 ± 0.36 [ > 32] | 0.37 ± 0.11 [ > 270] | 0.18 ± 0.02 [ > 555] |
|                   |           |                 | CPE     | 2.4 ± 0.22 [ > 41] | 0.37 ± 0.09 [ > 270] | 0.23 ± 0.02 [ > 434] |
|                   |           |                 | VTR     | 2.9 ± 0.95 [ > 34] | 0.48 ± 0.19 [ > 208] | 0.29 ± 0.10 [ > 344] |
|                   |           | M-1999          | CPE     | 1.5 [ > 66]*      | 0.36 [ > 277] | 0.14 [ > 714] |
|                   | HeV 1996  |                 | CPE     | 2.1 ± 0.57 [ > 47] | 0.57 ± 0.11 [ > 175] | 0.37 ± 0.09 [ > 270] |
|                   |           |                 | VTR     | 2.4 [ > 41]*      | 0.15 [ > 666] | 0.15 [ > 666] |
|                   | hPIV3     | Rec. JS-GFP     | REP     | 3.2 ± 0.50 [ > 32] | 0.44 ± 0.03 [ > 227] | 0.16 ± 0.02 [ > 625] |
|                   | MV        | Rec. rMVezGFP(3)| REP     | 1.9 ± 0.12 [ > 52] | 0.34 ± 0.07 [ > 294] | 0.27 ± 0.04 [ > 370] |
| **Pneumoviridae** | RSV       | Rec. rgRSV224(A2)| REP     | 3.3 ± 0.39 [ > 30] | 0.21 ± 0.04 [ > 476] | 0.28 ± 0.05 [ > 357] |
|                   | EBOV      | Rec. Mayinga-GFP| REP     | 2.6 ± 0.85 [ > 38] | 0.30 ± 0.02 [ > 333] | 7.79 ± 4.2 ± 12 |
|                   |           | Rec. Makona-ZsG | REP     | 2.1 ± 0.07 [ > 47] | 0.33 ± 0.03 [ > 303] | 3.85 ± 0.09 [ > 25] |
|                   |           | Makona          | FPU     | 2.1 ± 0.02 [ > 47] | 0.60 ± 0.08 [ > 166] | ND [ND] |
|                   | SUDV      | Gulu            | FFU     | 2.5 [40] | 0.70 ± 0.08 [ > 142] | 9.57 [ > 10] |
|                   | RAVV      | Ravn            | FFU     | 0.92 [ > 108] | 0.16 [ > 625] | 0.30 [ > 333] |
|                   |           |                 | FTR     | 7.4 [ > 16] [ > 13] | 0.73 ± 0.16 [ > 136] | 10.8 ± 4.9 [ > 9] |
|                   |           |                 | VTR     | 3.0 [ > 33] | 0.16 [ > 625] | 6.07 [ > 16] |
| **Filoviridae**   | EBOV      | Rec. Mayinga-GFP| REP     | > 50 [ND] | 44.6 [ > 2] | > 50 [ND] |
|                   | SUDV      | Gulu            | FFU     | > 50 [ND] | 44.6 [ > 2] | > 50 [ND] |
| **Phenuiviridae** | RVFV      | Rec. ZH501-GFP  | REP     | > 50 [ND] | 44.6 [ > 2] | > 50 [ND] |

EC_{50}, 50% effective inhibition concentration; SI, selective index = EC_{50}/CC_{50}; REP, reporter; CPE, cytopathic effect; VTR, virus titer reduction; FFU, focus-forming unit; ND, not determined; Rec, recombinant; *, data adapted from (Hotard et al., 2017). Mean values with ± standard deviation values were derived from a minimum of 2 independent experiments performed in biological quadruplicate.
quantified EBOV infection by the percentage of EBOV antigen-positive focus-forming units (FFUs) detected (Fig. 6d–e). We observed dose-dependent inhibition of FFU formation with R1479 and 2′dF-4′N3-C treatment, but did not detect significant inhibition by 2′F-4′N3-C (Fig. 6d, Table 1).

3.7. R1479 and 2′dF-4′N3-C potently inhibit SUDV

We then tested the 3 compounds against the Gulu variant of SUDV (genus *Ebolavirus*, species *Sudan ebolavirus*), a phylogenetically divergent relative of EBOV which prior to 2014 was responsible for the largest filovirus outbreak in humans (Lamunu et al., 2004; Sanchez and Rollin, 2005). R1479 and 2′dF-4′N3-C inhibited SUDV with efficacy similar to that observed with EBOVs by the FFU assay (Fig. 7a), with EC50 values of 2.5 μM (R1479) and 0.7 μM (2′dF-4′N3-C). Accordingly, 2′F-4′N3-C inhibited SUDV less potently than the other compounds, with an EC50 value of approximately 10 μM (Table 1). We further evaluated the antiviral activity of these 3 cytidine analogs against SUDV by measuring infectious virus yield (Fig. 7b). Both R1479 and 2′dF-4′N3-C reduced infectious SUDV titers by > 4 orders of magnitude at concentrations of 25 μM and 6.25 μM, respectively, with respective EC50 values of 0.92 μM and 0.16 μM. On the other hand, 2′F-4′N3-C only reduced infectious virus yield by approximately 1.5 orders of magnitude at the highest concentration used in the assay (12.5 μM) (Fig. 7b).

3.8. R1479 and 2′dF-4′N3-C potently inhibit RAVV

Having determined the antiviral activity of these compounds against phylogenetically divergent members of the genus *Ebolavirus*, we proceeded to test them against another filovirus, Ravn virus (RAVV) (genus *Marburgvirus*, species *Marburg marburgvirus*), which, when compared with EBOV and SUDV, was determined to be the most phylogenetically divergent member of the genus *Marburgvirus* (~67–68% nucleotide divergence) (Towner et al., 2006). Using our FFU assay, we observed that R1479 inhibited RAVV with 3-fold lower potency than EBOV or SUDV, with an EC50 value of 7.4 μM (Fig. 8a, Table 1). 2′dF-4′N3-C and 2′F-4′N3-C, however, inhibited RAVV similarly to EBOV and SUDV, with EC50 values of 0.73 μM and 10.8 μM, respectively. We then measured infectious RAVV production in the presence of the 3 compounds. Similar to what we observed for SUDV, both R1479 and 2′dF-4′N3-C reduced infectious RAVV titers by over 4 orders of magnitude at concentrations of 50 μM and 6.25 μM, respectively, with respective EC50 values of 0.73 μM and 10.8 μM, respectively. We then measured infectious RAVV production in the presence of the 3 compounds. Similar to what we observed for SUDV, both R1479 and 2′dF-4′N3-C reduced infectious RAVV titers by over 4 orders of magnitude at concentrations of 50 μM and 6.25 μM, respectively, with respective EC50 values of 0.73 μM and 10.8 μM, respectively. 2′F-4′N3-C reduced RAVV titers by roughly 1.5 orders of magnitude at the highest concentration used (25 μM), with an EC50 value of 6 μM (Fig. 8b, Table 1).

3.9. 2′F-4′N3-C potently inhibits NiV in human primary small airway epithelial cells

To verify the antiviral activity observed in the NCI-H358 cell line, we performed reporter and CPE assays for NiV using human primary
small airway epithelial cells (SAECs), which have been shown to support robust NiV replication (Escaffre et al., 2013). For both the reporter and CPE assays which utilized the recombinant reporter NiV-GFP2AM virus, we observed potent inhibition by 2′F-4′N3-C, with respective EC50 values of 0.34 and 0.56 μM (Fig. 9a–b, Table 2). The inhibition of both GFP and CPE could be visually observed, as treatment with 2′F-4′N3-C at 1.56 μM completely abolished GFP expression as well as CPE in the SAECs (Fig. 9c). On the other hand, we observed markedly lower antiviral activity for R1479 and 2′diF-4′N3-C, which indicates that their respective intracellular NTP levels were likely lower than their levels observed in NCI-H358 cells.

3.10. 2′diF-4′N3-C inhibits Marburg virus infection in human primary small airway epithelial cells

Since filovirus-pseudotyped lentiviruses can efficiently transduce airway epithelial cells in vivo (Kobinger et al., 2001), we proceeded to evaluate the antiviral activities of these nucleosides in SAECs against a reporter Marburg virus (MARV-ZsG) expressing a green fluorescent protein. In cells treated with serial dilutions of 2′diF-4′N3-C, we observed a dose-dependent inhibition of MARV infection by FFU assay; whereas R1479 and 2′F-4′N3-C did not show any significant inhibition (Fig. 10a–b, Table 2). The comparatively higher EC50 value for 2′diF-4′N3-C against MARV-ZsG in SAECs (3.59 μM) than what was observed for RAVV in NCI-H358 cells (0.73 μM) is likely due to lower intracellular NTP levels.

4. Discussion

In this study, we characterized the antiviral properties of R1479 and its analogs 2′F-4′N3-C and 2′diF-4′N3-C using both cell-free and cell-based assays. Despite the presence of 3′-OH group in each analog, all 3
compounds behaved like conventional non-obligatory RNA synthesis chain terminators in cell-free RSV polymerase assays (Deval et al., 2015). In order for nucleoside analogs to retain their antiviral function inside a cell, multiple cellular kinases are required to convert them to the active triphosphate form (Ray and Hitchcock, 2009). To better understand the cell type-dependent variability we previously observed with R1479 antiviral activity (Hotard et al., 2017), we measured cellular levels of R1479-TP in four different cell lines, and observed 2-3 fold higher levels of R1479-TP, 2′F-4′N3′-CTP, and 2′diF-4′N3′-CTP in NCI-H358 cells than in HeLa cells. The comparatively elevated NTP levels observed in NCI-H358 cells than in HeLa cells. The comparatively elevated NTP levels observed in NCI-H358 cells may be attributed to higher expression levels of uridine-cytidine kinases, which catalyze the presumed initial rate-limiting step of phosphorylating uridine and cytidine nucleosides (Van Rompay et al., 2001). Characterizing the NCI-H358 cell line as the optimal line to use in this study highlights the importance of conducting antiviral screens of nucleoside analog libraries. We have observed significantly decreased antiviral activity for R1479, 2′F-4′N3′-C, and 2′diF-4′N3′-C in Huh7 cells against reporter EBOVs (data not shown), which is likely explained by overall lower phosphorylation levels of these cytidine analogs in this cell line (Fig. 2a). The higher potency of 2′F-4′N3′-C, and 2′diF-4′N3′-C over R1479 against paramyxoviruses, however, cannot solely be attributed to NTP levels, since R1479-TP levels were higher than 2′F-4′N3′-CTP levels in these cells (Fig. 2b). Moreover, the change in rank order of anti-filoviral potency in the cell-based assays suggests that the differences in antiviral activity are due to differential recognition, or discrimination, of these NTP analogs by viral polymerases. Our gel-based biochemical assay using RSV polymerase provides qualitative results and informs mainly on the mechanism of action of each compound, demonstrating substrate recognition and chain termination (Fig. 1). It does not provide enough information to rank order potencies and/or discrimination between the three nucleotides (Deval et al., 2015). Evaluation of these compounds in primary human SAECs confirmed the potent anti-NiV activity of 2′F-4′N3′-C (Fig. 9) and the anti-MARV activity of 2′diF-4′N3′-C (Fig. 10). Our study did not include two other related nucleosides 2′-deoxy-2′-β-fluoro-4′-azidocytidine (RO-0622) and 2′-deoxy-2′-β-hydroxy-4′-azidocytidine (RO-9187) (Klumpp et al., 2008) because they had little to no antiviral activity against both NiV and EBOV, respectively (data not shown). Our results warrant further studies comparing the antiviral potency of these NTP analogs against recombinant paramyxovirus and filovirus polymerases, although technical challenges have precluded such work only until very...
recently (Jordan et al., 2018). The ability of these cytidine analogs to reduce henipavirus and filovirus infectious yields by over 4 log TCID_{50}/mL mirrors viral inhibition by GS-441524 (a 1′-cyano-modified adenosine analog) and its phosphoramidate nucleotide prodrug GS-5734 (Lo et al., 2017). GS-5734 inhibited filoviruses and coronaviruses in non-human primate and mouse models, respectively, and is currently in phase 2 clinical trials for treatment of EBOV disease (EVD) (Sheahan et al., 2017; Warren et al., 2016). Favipiravir, also known at T-705, is a broad-spectrum small molecule nucleoside precursor originally developed to treat influenza A virus; it also decreased EBOV infectious yield by 4 log TCID_{50}/mL, albeit at high concentrations (1000 μM) by a yet-undefined mechanism (Baranovich et al., 2013; Oestereich et al., 2014). BCX4430 is an adenosine nucleoside analog with variable in vitro broad-spectrum activity across 8 virus families including Filoviridae, and is currently in phase 1 clinical trials for treating EVD (Taylor et al., 2016; Warren et al., 2014). Although BCX4430 inhibits HCV polymerase similarly to conventional chain terminators and also reduces infectious filovirus yield, its mechanism of action against negative-strand viruses is unclear. While neither R1479 nor its 2′-fluoro-modified analogs are viable candidates for antiviral therapeutics due to variable incorporation by host mitochondrial RNA and DNA polymerases (Arnold et al., 2012; Clarke et al., 2015), they provide an initial comparison of filo-
and paramyxovirus susceptibility to 4′-modified nucleosides. Our study provides evidence supporting the development of 4′-modified nucleosides with near-equivalent potency not only against 3 Mononegavirales order families, but also against the positive-sense Flaviviridae family. Developing a small-molecule, broad-spectrum therapeutic to treat phylogenetically divergent viral infections that share significant epidemiological and clinical overlap (e.g., EBOV and yellow fever virus; NiV and Japanese encephalitis virus) would benefit clinicians with no access to rapid diagnostics amidst an outbreak of these serious viral infections.

### Table 2
Mean antiviral activity of R1479, 2′F-4′N₃-C, and 2′dif-4′N₃-C in primary human small airway epithelial cells.

| Family     | Virus | Species/Variant | Assay | EC₅₀ (µM) [SI] |
|------------|-------|----------------|-------|----------------|
|            |       |                |       | R1479          | 2′dif-4′N₃-C | 2′F-4′N₃-C |
| Paramyxoviridae | NiV   | Rec. M-GFP2AM  | REP   | > 50 [ND]      | 2.61 [ > 19] | 0.34 [ > 147] |
|             |       |                | CPE   | > 50 [ND]      | 7.09 [ > 7]  | 0.56 [ > 89]  |
| Filoviridae | MARV  | Rec. Bat371-ZsG| FFU   | > 50 [ND]      | 3.59 ± 0.32 [ > 13] | > 50 [ND] |

EC₅₀, 50% effective inhibition concentration; SI, selective index = EC₅₀/CC₅₀; REP, reporter; CPE, cytopathic effect; FFU, focus-forming unit; ND, not determined; Rec, recombinant. Mean values with ± standard deviation values were derived from a minimum of 2 independent experiments performed in biological quadruplicate.

### Fig. 10.
2′dif-4′N₃-C inhibits reporter Marburg virus (MARV) infection in human primary small airway epithelial cells. (a) Representative dose response curves for R1479 (green circles), 2′F-4′N₃-C (blue triangles), and 2′dif-4′N₃-C (red squares) against recombinant reporter MARV expressing a green fluorescent protein (ZsGreen1) using a focus forming unit (FFU) assay. FFU assays for R1479 and 2′F-4′N₃-C were performed once, and was repeated once for 2′dif-4′N₃-C. Data points and error bars indicate the mean value and standard deviation of 4 biological replicates. (b) Representative composite micrographs of MARV GFP+ FFUs in individual wells of a 96-well plate of 2′dif-4′N₃-C -treated, MARV-infected SAECs. Concentrations of 2′dif-4′N₃-C (in µM) are indicated above each pictured well.
Acknowledgments

We thank the nucleoside chemistry group at Alios for synthesizing the compounds and their NPAs, and Julian Symons and Leo Beigelman from Alios for supporting this work. We thank Mike Flint and Tatyana Klimova for helpful comments in reviewing the manuscript. We also thank Cesar A. Albarino for providing the MARV-ZsG virus. The findings and conclusions in this report are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention. This work was financially supported by CDC core funding.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.antiviral.2018.03.009.

References

Albarino, C.G., Ciglione, C.K., Islam, M., Mire, C.E., Geisbert, T.W., Fenton, H., 2017. Outbreaks Chronology: Ebola Virus Disease. JAMA 317, 733–742.

Arndt, J., Seiler, J., signalDeval, J., Hong, J., Wang, G., Taylor, J., Smith, L.K., Fung, A., Stevens, S.K., Liu, H., Jin, Geisbert, T.W., Mire, C.E., Geisbert, J.B., Chan, Y.P., Agans, K.N., Feldmann, F., Fenton, F., CDC, 2017. Outbreaks Chronology: Ebola Virus Disease.

Arndt, J., Seiler, J., signalDeval, J., Hong, J., Wang, G., Taylor, J., Smith, L.K., Fung, A., Stevens, S.K., Liu, H., Jin, Geisbert, T.W., Mire, C.E., Geisbert, J.B., Chan, Y.P., Agans, K.N., Feldmann, F., Fenton, F., CDC, 2017. Outbreaks Chronology: Ebola Virus Disease.

Baranovich, T., Wong, S.S., Armstrong, J., Marjuki, H., Webby, R.J., Webster, R.G., Arnold, J.J., Sharma, S.D., Fenton, F., CDC, 2017. Outbreaks Chronology: Ebola Virus Disease.

Baranovich, T., Wong, S.S., Armstrong, J., Marjuki, H., Webby, R.J., Webster, R.G., Arnold, J.J., Sharma, S.D., Feng, J.Y., Ray, A.S., Smidansky, E.D., Kireeva, M.L., Cho, A., 2017. Outbreaks Chronology: Ebola Virus Disease.

Beigelman, L., 2015. Molecular basis for the selective inhibition of respiratory syncytial virus with perfluoro-4'-alpha-cyano-5-aza-7,9-di-furocytidine and 4'-azido-2'-deoxy-2',2'-dideoxy-2',2'-di-fluorocytidine. J. Med. Chem. 58, 2944–2950.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennett, M., Fullerton, J., 2014. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne flaviviruses. PLoS Negl. Trop. Med. 8, e2986.

Bennet
Towner, J.S., Khristova, M.L., Sealy, T.K., Vincent, M.J., Erickson, B.R., Baswiec, D.A., Hartman, A.L., Comer, J.A., Zaki, S.R., Stroher, U., Gomes da Silva, F., del Castillo, F., Rollin, P.E., Ksiazek, T.G., Nichol, S.T., 2006. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J. Virol. 80, 6497–6516.

Towner, J.S., Paragas, J., Dover, J.E., Gupta, M., Goldsmith, C.S., Huggins, J.W., Nichol, S.T., 2005. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 332, 20–27.

Van Rompay, A.R., Norda, A., Linden, K., Johansson, M., Karlsson, A., 2001. Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol. Pharmacol. 59, 1181–1186.

Veljkovic, V., Lisseau, P.M., Figadere, B., Glisic, S., Veljkovic, N., Perovic, V.R., Cavanaugh, D.P., Branch, D.R., 2015. Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Res 4, 34.

Wang, G., Deval, J., Hong, J., Dyatkin, N., Prhavc, M., Taylor, J., Fung, A., Jio, Z., Stevens, S.K., Serebryany, V., Liu, J., Zhang, Q., Tam, Y., Chanda, S.M., Smith, D.B., Symons, J.A., Blatt, L.M., Beigelman, L., 2015. Discovery of 4-chloromethyl-2′-deoxy-3′,5′-di-O-isobutyryl-2′-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J. Med. Chem. 58, 1862–1878.

Warren, T.K., Jordan, R., Lo, M.K., Ray, A.S., Mackman, R.L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H.C., Larson, N., Strickley, R., Wells, J., Stuthman, K.S., Van Tongeren, S.A., Garza, N.L., Donnelly, G., Shurtleff, A.C., Retterer, C.J., Gharabeh, D., Zamani, R., Keny, T., Eaton, B.P., Grimes, E., Welch, L.S., Gomba, L., Wilhelmsen, C.L., Nichols, D.K., Nuss, J.E., Nagle, E.R., Kugelman, J.R., Palacios, G., Doerrfler, E., Neville, S., Carsa, E., Clarke, M.O., Zhang, L., Lew, W., Ross, B., Wang, Q., Chun, K., Wolfe, L., Batusis, D., Park, Y., Stray, K.M., Trancheva, L., Feng, J.Y., Baraukas, O., Xu, Y., Wong, P., Braun, M.R., Flint, M., McMullan, L.K., Chen, S.S., Fearon, R., Swaminathan, S., Meyers, D.L., Spiropoulou, C.F., Lee, W.A., Nichol, S.T., Cihlar, T., Bavari, S., 2016. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381–385.

Warren, T.K., Wells, J., Panchal, R.G., Stuthman, K.S., Garza, N.L., Van Tongeren, S.A., Dong, L., Retterer, C.J., Eaton, B.P., Pegoraro, G., Henno, S., Banta, S., Kotian, P., Chen, X., Taubenheim, B.R., Welch, L.S., Minning, D.M., Babi, V.S., Sheridan, W.P., Bavari, S., 2014. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508, 402–405.

Welch, S.R., Guerrero, L.W., Chakrabarti, A.K., McMullan, L.K., Flint, M., Bluemling, G.R., Painter, G.R., Nichol, S.T., Spiropoulou, C.F., Albarino, C.G., 2016. Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems. Antivir. Res. 136, 9–18.

Zhang, L., Bokreyev, A., Thompson, C.I., Watson, B., Peeples, M.E., Collins, P.L., Pickles, R.J., 2005. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J. Virol. 79, 1113–1124.